Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 21, 20 December 2023
Open
Access | Article
An introduction to cancer vaccine, chimeric antigen receptor (CAR) T-cell and immune checkpoint blockade
* Author to whom correspondence should be addressed.
Abstract
Cancer immunotherapy has been a hot topic of cancer therapy discussion for over decades. Several successful cancer immunotherapies have already existed for about 30 years, however it is just in the past decade that immunotherapy has achieved broad breakthrough on patient survival in multiple high-incidence cancer indications. Immunotherapy, as a promising therapy depending mainly on the mechanism that immune cells work to eliminate cancer cells, has three hot topics recently. Cancer vaccine is a therapeutic vaccine that typically involves exogenous administration of selected tumour antigens to activate dendritic cells (DCs), or even DCs themselves in order to initiate and stimulate immune response to tumour cells, regain their control over tumour growth, induce existed tumour regression and eradicate minimal residual disease. Chimeric antigen receptor (CAR) T-cell therapy uses a patient's own T cells, but genetically engineered to express a synthetic receptor that binds to a tumour antigen more precisely and efficiently, to serve as more effective army against tumours. Immune checkpoint blockade (ICB) depends on blocking certain receptors and their ligands involved in pathways that attenuate T cell activation — for example, cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1) and its ligand, PDL1 — to restore T cells’ activity and prevent acquired peripheral tolerance to tumour antigens. This review gives a brief introduction to how human immune system works and a basic overview on the principles of cancer vaccine, chimeric antigen receptor (CAR) T-cell and immune checkpoint blockade (ICB).
Keywords
immunotherapy, cancer vaccine, chimeric antigen receptor T-cell, immune checkpoint blockade.
References
1. Akiko Iwasaki & Ruslan Medzhitov. Control of adaptive immunity by the innate immune system. Nature Immunology 16(4), 343-353(2015).
2. Anguille, S, Smits, EL, Lion, E. et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncology 15(7), E257-E267(2014).
3. Lindsay B. Nicholson. The immune system. Essays in Biochemistry 60, 275–301(2016).
4. Jian Liu, Minyang Fu, Manni Wang. et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. Journal of Hematology & Oncology 15, 28(2022).
5. Mansi Saxena, Sjoerd H. van der Burg, Cornelis J. M. Melief and Nina Bhardwaj. Therapeutic cancer vaccines. Nature reviews cancer 21, 360-378(2021).
6. Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803–808 (2015).
7. Rosalia, R. A. et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T -cell activation. Immunol 43, 2554–2565 (2013).
8. Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81–85 (2015).
9. Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature Communications 8, 1136(2017).
10. Steven Feins, Weimin Kong, Erik F. Williams, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. American Journal of Hematology 94, S3-S9(2019).
11. Michel Sadelain, Renier Brentjens, and Isabelle Rivière, The basic principles of chimeric antigen receptor design. Cancer Discovery 3(4), 388-398(2013).
12. Ruella M, Xu J, Barrett DM, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 24(10), 1499-1503(2018).
13. Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumour rejection. Nat Med 13, 1440–1449(2007).
14. Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 8(320), 320-323(2016).
15. Ruella M, Xu J, Barrett DM, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 24(10), 1499-1503(2018).
16. Drew M. Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews cancer 12(4), 252-264(2012).
17. Alan J. Korman , Sarah C. Garrett-Thomson and Nils Lonberg. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery 21(2), 163-163(2022).
18. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).
19. Dodagatta-Marri, E. et al. α-PD-1 therapy elevates Treg/Th balance and increases tumour cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. J. Immunother. Cancer 7, 62 (2019).
20. Dong, H. et al. Tumour-associated B7-H1 promotes T -cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).
21. T an, C. L. et al. PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J. Exp. Med. 218(1), e20182232 (2021).
22. Walker, L. S. & Sansom, D. M. Confusing signals: recent progress in CTLA-4 biology. Trends in Immunology. 36(2), 63–70 (2015).
23. Dong, H., Zhu, G., T amada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T -cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365–1369 (1999).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-215-2
- ISBN (Online)
- 978-1-83558-216-9
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/21/20230809
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited